drugset / Trial / NCT03022500
Pulmonary sarcomatoid_MEDI4736+Treme
NaSingle-groupOpen-labelTreatment
Summary
To understand efficacy of Durvalumab(MEDI4736)+ Tremelimumab in Metastatic/relapsed pulmonary sarcomatoid carcinoma
Timeline
- Start
- 2017-05-18
- Primary completion
- 2018-02-28
- Completion
- 2019-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 750 mg | — |
| Subject | Tremelimumab | Monoclonal antibody | 75 mg | — |